IFIH1 and juvenile dermatomyositis: Sabbagh et al. in 2019 reported the use of tofacitinib, a JAK inhibitor, leading to clinical improvement within 6 months in two anti-MDA5 antibody-positive JDM refractory to multiple agents including rituximab [26].